KZR Kezar Life Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KZR

Price (delayed)

$0.8049

Market cap

$58.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$42.04M

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule ...

Highlights
The debt has contracted by 11% YoY and by 3.2% from the previous quarter
The quick ratio has shrunk by 55% YoY and by 16% QoQ
The net income has contracted by 49% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://kezarlifesciences.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KZR
Market
Shares outstanding
72.8M
Market cap
$58.6M
Enterprise value
$42.04M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
8.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.01
Earnings
Revenue
$7M
EBIT
-$100.32M
EBITDA
-$99.25M
Free cash flow
-$83.45M
Per share
EPS
-$1.4
Free cash flow per share
-$1.15
Book value per share
$2.58
Revenue per share
$0.1
TBVPS
$3.05
Balance sheet
Total assets
$221.24M
Total liabilities
$33.67M
Debt
$18.93M
Equity
$187.57M
Working capital
$189.21M
Liquidity
Debt to equity
0.1
Current ratio
11.66
Quick ratio
11.35
Net debt/EBITDA
0.17
Margins
EBITDA margin
-1,417.9%
Gross margin
100%
Net margin
-1,455.3%
Operating margin
-1,591.8%
Efficiency
Return on assets
-40%
Return on equity
-45.9%
Return on invested capital
-44.1%
Return on capital employed
-49.3%
Return on sales
-1,433.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KZR stock price

How has the Kezar Life Sciences stock price performed over time
Intraday
1.89%
1 week
1.89%
1 month
-9.96%
1 year
-66.04%
YTD
-15.04%
QTD
-10.73%

Financial performance

How have Kezar Life Sciences's revenue and profit performed over time
Revenue
$7M
Gross profit
$7M
Operating income
-$111.42M
Net income
-$101.87M
Gross margin
100%
Net margin
-1,455.3%
The company's operating income has shrunk by 57% YoY and by 15% QoQ
The net income has contracted by 49% YoY and by 16% from the previous quarter
The net margin has contracted by 16% from the previous quarter
The operating margin has contracted by 15% from the previous quarter

Growth

What is Kezar Life Sciences's growth rate over time

Valuation

What is Kezar Life Sciences stock price valuation
P/E
N/A
P/B
0.31
P/S
8.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.01
The EPS has declined by 39% year-on-year and by 15% since the previous quarter
The price to book (P/B) is 82% less than the 5-year quarterly average of 1.7 and 48% less than the last 4 quarters average of 0.6
KZR's equity is down by 30% year-on-year and by 13% since the previous quarter

Efficiency

How efficient is Kezar Life Sciences business performance
KZR's ROE has shrunk by 82% YoY and by 27% QoQ
The return on assets has dropped by 72% year-on-year and by 25% since the previous quarter
The company's return on invested capital has shrunk by 56% YoY and by 27% QoQ
The return on sales has declined by 16% since the previous quarter

Dividends

What is KZR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KZR.

Financial health

How did Kezar Life Sciences financials performed over time
The quick ratio has shrunk by 55% YoY and by 16% QoQ
KZR's current ratio has dropped by 55% year-on-year and by 16% since the previous quarter
The debt is 90% less than the equity
KZR's equity is down by 30% year-on-year and by 13% since the previous quarter
KZR's debt to equity is up by 25% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.